Martin S. Angst

Input characteristics and bioavailability after administration of immediate and a new extended-release formulation of hydromorphone in healthy volunteers.

The mu-opioid agonist remifentanil attenuates hyperalgesia evoked by blunt and punctuated stimuli with different potency: a pharmacological evaluation of the freeze lesion in humans.

The site of action of epidural fentanyl in humans: the difference between infusion and bolus administration.

The site of action of epidural fentanyl infusions in the presence of local anesthetics: a minimum local analgesic concentration infusion study in nulliparous labor.

Short-term infusion of the mu-opioid agonist remifentanil in humans causes hyperalgesia during withdrawal.

Comparative analgesic and mental effects of increasing plasma concentrations of dexmedetomidine and alfentanil in humans.

Dexmedetomidine and opioid interactions: defining the role of dexmedetomidine for intensive care unit sedation.

Management of perioperative pain in patients chronically consuming opioids.

Opioid tolerance and hyperalgesia in chronic pain patients after one month of oral morphine therapy: a preliminary prospective study.

Opioid-induced hyperalgesia: a qualitative systematic review.

Blockade of the complement C5a receptor reduces incisional allodynia, edema, and cytokine expression.

Experimental heat pain for detecting pregnancy-induced analgesia in humans.

Pharmacology of drugs formulated with DepoFoam: a sustained release drug delivery system for parenteral administration using multivesicular liposome technology.

Comment on Koltzenburg et al.: Differential sensitivity of three experimental pain models in detecting the analgesic effects of transdermal fentanyl and buprenorphine. Pain 2006;126:165-74.

When opioids cause pain.

Morphine reduces local cytokine expression and neutrophil infiltration after incision.

Chronic morphine administration enhances nociceptive sensitivity and local cytokine production after incision.

Local and systemic release of cytokines, nerve growth factor, prostaglandin E2, and substance P in incisional wounds and serum following cesarean delivery.

Opioid-induced hyperalgesia in humans: molecular mechanisms and clinical considerations.

No evidence for the development of acute tolerance to analgesic, respiratory depressant and sedative opioid effects in humans.

Epidural interferon gamma-immunoreactivity: a biomarker for lumbar nerve root irritation.

Cytokine evaluation in individuals with low back pain using discographic lavage.

Intrathecal cyclooxygenase inhibitors in humans: don't throw in the towel!

Opioid pharmacotherapy for chronic non-cancer pain in the United States: a research guideline for developing an evidence-base.

Identification of a complex between fibronectin and aggrecan G3 domain in synovial fluid of patients with painful meniscal pathology.

Ketamine for managing perioperative pain in opioid-dependent patients with chronic pain: a unique indication?

Continuous subcutaneous instillation of bupivacaine compared to saline reduces interleukin 10 and increases substance P in surgical wounds after cesarean delivery.

The endogenous opioid system is not involved in modulation of opioid-induced hyperalgesia.

Opioid pharmacogenomics using a twin study paradigm: methods and procedures for determining familial aggregation and heritability.

The role of interleukin-1 in wound biology. Part I: Murine in silico and in vitro experimental analysis.

The role of interleukin-1 in wound biology. Part II: In vivo and human translational studies.

Effect of a preemptive femoral nerve block on cytokine release and hyperalgesia in experimentally inflamed skin of human volunteers.

Selective nociceptor activation in volunteers by infrared diode laser.

Sensitivity of gait parameters to the effects of anti-inflammatory and opioid treatments in knee osteoarthritis patients.

Sex Differences in Reported Pain Across 11,000 Patients Captured in Electronic Medical Records.